Peptides
The six peptides a state-licensed pharmacy may compound with a prescription under the interim HHS policy. For every other peptide, see the full status table.
| Peptide | Status | Forms HHS allows |
|---|---|---|
| BPC-157 | HHS interim policy, prescription only | Injection (SC/IM), oral, topical |
| TB-500 | HHS interim policy, prescription only | Injection (SC/IM) |
| MOTS-c | HHS interim policy, prescription only | Injection (SC/IM) |
| KPV | HHS interim policy, prescription only | Topical, oral |
| Semax | HHS interim policy, prescription only | Intranasal |
| Epitalon | HHS interim policy, prescription only | Injection (SC/IM), intermittent courses |
Checked against the HHS policy and Appendix B on November 5, 2026. Not FDA-approved.
Other substances
- Sermorelin: Ingredient of GEREF (approved, withdrawn from sale)
- NAD+ injections: FDA 503A Category 1, under evaluation
- Glutathione injections: FDA 503A Category 1, under evaluation